Guillaume Vesselle1, Camille Quirier-Leleu2, Stéphane Velasco3, Florian Charier2, Christine Silvain2, Samy Boucebci3, Pierre Ingrand4, Jean-Pierre Tasu3. 1. Diagnostic, Functional and Therapeutic Imaging Department, Poitiers University Hospital, 2 rue de la Milétrie, 86021, Poitiers Cedex, France. guillaumevesselle@gmail.com. 2. Department of Gastroenterology, Poitiers University Hospital, 2 rue de la Milétrie, 86021, Poitiers Cedex, France. 3. Diagnostic, Functional and Therapeutic Imaging Department, Poitiers University Hospital, 2 rue de la Milétrie, 86021, Poitiers Cedex, France. 4. Epidemiology and Biostatistics, Clinical Investigation Center INSERM CIC-P 802, Poitiers University Hospital, 2 rue de la Milétrie, 86021, Poitiers Cedex, France.
Abstract
OBJECTIVES: To identify clinical and imaging features associated with complete response (CR) to first session of transarterial chemoembolization (TACE) with drug-eluting beads (DEB) in patients with hepatocellular carcinoma. METHODS: In this prospective historical cohort, 172 patients with 315 tumours who received at least one DEB-TACE from 2007 to 2013 were studied. Imaging response was evaluated according to the modified Response Evaluation Criteria in Solid Tumours (mRECIST). Age, gender, aetiology of cirrhosis, Child and BCLC scores, particles size, location in the liver, size of the tumour, presence of a capsule, hypervascularisation on DSA and CT/MRI scans, and blush extinction were analysed. RESULTS: After one session of treatment, CR was observed in 36 % of the 315 tumours treated. Nodule size, location in the liver, and complete blush extinction on DSA was statistically correlated to complete response, whereas capsule aspect on imaging and demographic criteria were not. In multivariate analysis only, location in the liver and nodule size were significant features. CONCLUSIONS: Tumour location in the segments 1 and 4 is a pejorative factor for CR, whereas tumour size <5 cm is a positive predictive factor. These criteria could, therefore, be taken into consideration to improve the selection of patients for DEB-TACE. KEY POINTS: • Literature on predictive factors of complete response after DEB-TACE is under-studied. • Tumour size <5 cm is associated with complete response. • Location in segments 1 or 4 is a pejorative factor for response. • No demographic parameter influences complete response.
OBJECTIVES: To identify clinical and imaging features associated with complete response (CR) to first session of transarterial chemoembolization (TACE) with drug-eluting beads (DEB) in patients with hepatocellular carcinoma. METHODS: In this prospective historical cohort, 172 patients with 315 tumours who received at least one DEB-TACE from 2007 to 2013 were studied. Imaging response was evaluated according to the modified Response Evaluation Criteria in Solid Tumours (mRECIST). Age, gender, aetiology of cirrhosis, Child and BCLC scores, particles size, location in the liver, size of the tumour, presence of a capsule, hypervascularisation on DSA and CT/MRI scans, and blush extinction were analysed. RESULTS: After one session of treatment, CR was observed in 36 % of the 315 tumours treated. Nodule size, location in the liver, and complete blush extinction on DSA was statistically correlated to complete response, whereas capsule aspect on imaging and demographic criteria were not. In multivariate analysis only, location in the liver and nodule size were significant features. CONCLUSIONS:Tumour location in the segments 1 and 4 is a pejorative factor for CR, whereas tumour size <5 cm is a positive predictive factor. These criteria could, therefore, be taken into consideration to improve the selection of patients for DEB-TACE. KEY POINTS: • Literature on predictive factors of complete response after DEB-TACE is under-studied. • Tumour size <5 cm is associated with complete response. • Location in segments 1 or 4 is a pejorative factor for response. • No demographic parameter influences complete response.
Authors: J-L Raoul; B Sangro; A Forner; V Mazzaferro; F Piscaglia; L Bolondi; R Lencioni Journal: Cancer Treat Rev Date: 2010-08-17 Impact factor: 12.111
Authors: Robert J Lewandowski; Dingxin Wang; James Gehl; Bassel Atassi; Robert K Ryu; Kent Sato; Albert A Nemcek; Frank H Miller; Mary F Mulcahy; Laura Kulik; Andrew C Larson; Riad Salem; Reed A Omary Journal: J Vasc Interv Radiol Date: 2007-10 Impact factor: 3.464
Authors: Mary K Bryant; David P Dorn; Jessica Zarzour; J Kevin Smith; David T Redden; Souheil Saddekni; Ahmed Kamel Abdel Aal; Stephen H Gray; Devin E Eckhoff; Derek A Dubay Journal: HPB (Oxford) Date: 2013-08-26 Impact factor: 3.647
Authors: Luigi Bolondi; Andrew Burroughs; Jean-François Dufour; Peter R Galle; Vincenzo Mazzaferro; Fabio Piscaglia; Jean Luc Raoul; Bruno Sangro Journal: Semin Liver Dis Date: 2013-02-08 Impact factor: 6.115
Authors: Johannes Lammer; Katarina Malagari; Thomas Vogl; Frank Pilleul; Alban Denys; Anthony Watkinson; Michael Pitton; Geraldine Sergent; Thomas Pfammatter; Sylvain Terraz; Yves Benhamou; Yves Avajon; Thomas Gruenberger; Maria Pomoni; Herbert Langenberger; Marcus Schuchmann; Jerome Dumortier; Christian Mueller; Patrick Chevallier; Riccardo Lencioni Journal: Cardiovasc Intervent Radiol Date: 2009-11-12 Impact factor: 2.740
Authors: Jan B Hinrichs; Hoen-Oh Shin; Daniel Kaercher; Davut Hasdemir; Tim Murray; Till Kaireit; Carolin Lutat; Arndt Vogel; Bernhard C Meyer; Frank K Wacker; Thomas Rodt Journal: Eur Radiol Date: 2016-01-14 Impact factor: 5.315
Authors: Juferdy Kurniawan; Andri Sanityoso Sulaiman; Sahat Basana Romanti Ezer Matondang; Toar Jean Maurice Lalisang; Ening Krisnuhoni; Steven Zulkifly Journal: Case Reports Hepatol Date: 2017-09-27